Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Natural Killer Cells Display an Activated Phenotype but Reduced Effector Functions in Obese Patients

Sebastien Viel, Laurie Besson, Emily Charrier, Jacques Bienvenu, Emmanuel Disse, Thierry Walzer, Charles Dumontet

Blood (2015) 126 (23): 3430.

https://doi.org/10.1182/blood.V126.23.3430.3430

Published: 2015

Journal Articles

Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study

Lionel Karlin, Jacques Bienvenu, PhD, Rene-Olivier Casasnovas, MD, Marie-Helene Delfau-Larue, MD PhD, Pierre Feugier, MD PhD, Jehan Dupuis, MD, Tioka Rabeony, Christophe Ferme, MD, Catherine Sebban, MD, Pierre Soubeyran, MD PhD, Guillaume Cartron, MD, Alain Delmer, MD PhD, Dominique Bordessoule, MD, Pauline Brice, MD, Thierry Lamy, MD PhD, Sami Bousseta, Hervé Tilly, MD PhD, Gilles Andre Salles, MD PhD

Blood (2014) 124 (21): 4430.

https://doi.org/10.1182/blood.V124.21.4430.4430

Published: 2014

Journal Articles

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma

Ewa Lech-Maranda, Lucile Baseggio, Jacques Bienvenu, Carole Charlot, Françoise Berger, Dominique Rigal, Krzysztof Warzocha, Bertrand Coiffier, Gilles Salles

Blood (2004) 103 (9): 3529–3534.

https://doi.org/10.1182/blood-2003-06-1850

Published: 2004

Journal Articles

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome

Przemyslaw Juszczynski, Ewa Kalinka, Jacques Bienvenu, Grzegorz Woszczek, Maciej Borowiec, Tadeusz Robak, Marek Kowalski, Ewa Lech-Maranda, Lucile Baseggio, Bertrand Coiffier, Gilles Salles, Krzysztof Warzocha

Blood (2002) 100 (8): 3037–3040.

https://doi.org/10.1182/blood-2002-02-0654

Published: 2002

Journal Articles

Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome

Krzysztof Warzocha, Patricia Ribeiro, Jacques Bienvenu, Pascal Roy, Carole Charlot, Dominique Rigal, Bertrand Coiffier, Gilles Salles

Blood (1998) 91 (10): 3574–3581.

https://doi.org/10.1182/blood.V91.10.3574

Published: 1998

NARROW

Natural Killer Cells Display an Activated Phenotype but Reduced Effector Functions in Obese Patients

Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome

Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome

Email alerts

ASH Publications

American Society of Hematology

Natural Killer Cells Display an Activated Phenotype but Reduced Effector Functions in Obese Patients

Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma

Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome

Genetic Polymorphisms in the Tumor Necrosis Factor Locus Influence Non-Hodgkin's Lymphoma Outcome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only